Churchill Pharmaceuticals
3602 Horizon Drive
Suite 160
King Of Prussia
Pennsylvania
19406
United States
Website: https://www.churchillpharma.com
About Churchill Pharmaceuticals
Churchill Pharmaceuticals is focused on bringing value to cancer care by developing quality orally delivered oncology products with clinical profiles addressing efficacy, safety and efficiency.YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Mat Callahan
CSO: Bill Bosch
JOBS:
Please click here for Churchill Pharma job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
5 articles about Churchill Pharmaceuticals
-
Sun Pharma received approval from the U.S. Food and Drug Administration (FDA) for Yonsa (abiraterone acetate) to treat metastatic castration-resistant prostate cancer (mCRPC). Sun will launch the drug in the U.S. via a licensing deal with Churchill Pharmaceuticals, the original developer of the d...
-
Sun Pharma Announces USFDA Approval of YONSA® (abiraterone acetate) To Treat Metastatic Castration-Resistant Prostate Cancer In Combination With Methylprednisolone
5/23/2018
Sun Pharmaceutical Industries Ltd. and Churchill Pharmaceuticals, LLC. today announced that one of Sun Pharma’s wholly owned subsidiary companies has received approval from the U.S. Food and Drug Administration (FDA) for YONSA® (abiraterone acetate).
-
Churchill Pharmaceuticals Announces NDA Filing Acceptance For YONSA By The U.S. FDA
7/20/2017
-
Churchill Pharmaceuticals Expands Commercial Leadership Team
5/30/2017
-
Churchill Pharmaceuticals Announces Submission Of NDA For Novel Oral Formulation Of Prostate Cancer Treatment
5/23/2017